High-affinity anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide

Biochemical Journal

Volumn 473, Issue 11, 2016, Pages 1563-1578

  Rauth, Sabine ^a   Hinz, Dominik ^a   Börger, Michael ^a   Uhrig, Markus ^b   Mayhaus, Manuel ^b   Riemenschneider, Matthias ^b   Skerra, Arne ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

A ; Lipocalin; Neurodegeneration; Peptide; Protein engineering.

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; ANTICALIN; LIPOCALIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN; THIOFLAVINE; UNCLASSIFIED DRUG; PEPTIDE LIBRARY; PROTEIN BINDING;

ALZHEIMER DISEASE; ARTICLE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; ESCHERICHIA COLI; GENE LIBRARY; GENE MUTATION; HUMAN; MOLECULAR PATHOLOGY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE; THERMOSTABILITY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PEPTIDE LIBRARY; PROCEDURES; PROTEIN CONFORMATION;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; BINDING SITES; HUMANS; LIPOCALINS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING;

EID: 84975132596     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BCJ20160114     Document Type: Article

References (100)

1. Morgan, D. (2011) Immunotherapy for Alzheimer's disease. J. Intern. Med. 269, 54-63
2. Tanzi, R.E. and Bertram, L. (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555
3. Querfurth, H.W. and LaFerla, F.M. (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344
4. Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.H., Multhaup, G., Beyreuther, K. and Müller-Hill, B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736
5. Stine, Jr, W.B., Dahlgren, K.N., Krafft, G.A. and LaDu, M.J. (2003) In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278, 11612-11622
6. Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356
7. Haass, C. and Selkoe, D.J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell. Biol. 8, 101-112
8. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J. and Selkoe, D.J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.Nature416, 535-539
9. McDonald, R.J., Craig, L.A. and Hong, N.S. (2010) The etiology of age-related dementia is more complicated than we think. Behav. Brain Res. 214, 3-11
10. Citron, M. (2010) Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387-398
11. Doody, R.S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X. and Thomas, R.G. (2013) A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369, 341-350
12. Lannfelt, L., Moller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V. and Gellerfors, P. (2014) Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res. Ther. 6,16
13. Delrieu, J., Ousset, P.J., Caillaud, C. and Vellas, B. (2012) 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J. Neurochem. 120 Suppl 1, 186-193
14. Brody, D.L. and Holtzman, D.M. (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 31, 175-193
15. Qian, X., Hamad, B. and Dias-Lalcaca, G. (2015) The Alzheimer disease market. Nat. Rev. Drug Discov. 14, 675-676
16. Orgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., Kirby, L.C., Jouanny, P., Dubois, B., Eisner, L. and Flitman, S. (2003) Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46-54
17. Robinson, S.R., Bishop, G.M., Lee, H.G. and Munch, G. (2004) Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol. Aging 25, 609-615
18. DeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M. and Holtzman, D.M. (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 8850-8855
19. Bacskai, B.J., Kajdasz, S.T., McLellan, M.E., Games, D., Seubert, P., Schenk, D. and Hyman, B.T. (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 22, 7873-7878
20. Medecigo, M., Manoutcharian, K., Vasilevko, V., Govezensky, T., Munguia, M.E., Becerril, B., Luz-Madrigal, A., Vaca, L., Cribbs, D.H. and Gevorkian, G. (2010) Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries. J. Neuroimmunol. 223, 104-114
21. Cattepoel, S., Hanenberg, M., Kulic, L. and Nitsch, R.M. (2011) Chronic intranasal treatment with an anti-Aβ30-42 scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 6, e18296
22. Habicht, G., Haupt, C., Friedrich, R.P., Hortschansky, P., Sachse, C., Meinhardt, J., Wieligmann, K., Gellermann, G.P., Brodhun, M. and Gotz, J. (2007) Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc. Natl. Acad. Sci. U.S.A. 104, 19232-19237
23. Morgado, I., Wieligmann, K., Bereza, M., Ronicke, R., Meinhardt, K., Annamalai, K., Baumann, M., Wacker, J., Hortschansky, P. and Malesevic, M. (2012) Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment. Proc. Natl. Acad. Sci. U.S.A. 109, 12503-12508
24. Grönwall, C., Jonsson, A., Lindström, S., Gunneriusson, E., Ståhl, S. and Herne, N. (2007) Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides. J. Biotechnol. 128, 162-183
25. Hoyer, W., Grönwall, C., Jonsson, A., Ståhl, S. and Härd, T. (2008) Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation. Proc. Natl. Acad. Sci. U.S.A. 105, 5099-5104
26. Hanenberg, M., McAfoose, J., Kulic, L., Welt, T., Wirth, F., Parizek, P., Strobel, L., Cattepoel, S., Spani, C. and Derungs, R. (2014) Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease. J. Biol. Chem. 289, 27080-27089
27. Richter, A., Eggenstein, E. and Skerra, A. (2014) Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett. 588, 213-218
28. Åkerström, B., Borregaard, N., Flower, D.A. and Salier, J.-S. (2006) Lipocalins., Landes Bioscience, Georgetown, Texas
29. Schiefner, A. and Skerra, A. (2015) The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds. Acc. Chem. Res. 48, 976-985
30. Skerra, A. (2000) Lipocalins as a scaffold. Biochim. Biophys. Acta 1482, 337-350
31. Gebauer, M. and Skerra, A. (2012) Anticalins: small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol. 503, 157-188
32. Kim, H.J., Eichinger, A. and Skerra, A. (2009) High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J. Am. Chem. Soc. 131, 3565-3576
33. Schönfeld, D., Matschiner, G., Chatwell, L., Trentmann, S., Gille, H., Hülsmeyer, M., Brown, N., Kaye, P.M., Schlehuber, S., Hohlbaum, A.M. and Skerra, A. (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc. Natl. Acad. Sci. U.S.A. 106, 8198-8203
34. Gebauer, M., Schiefner, A., Matschiner, G. and Skerra, A. (2013) Combinatorial design of an Anticalin directed against the extra-domain B for the specific targeting of oncofetal fibronectin. J. Mol. Biol. 425, 780-802
35. Goetz, D.H., Holmes, M.A., Borregaard, N., Bluhm, M.E., Raymond, K.N. and Strong, R.K. (2002) The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell. 10, 1033-1043
36. Zagorski, M.G., Yang, J., Shao, H., Ma, K., Zeng, H. and Hong, A. (1999) Methodological and chemical factors affecting amyloid β peptide amyloidogenicity. Methods Enzymol. 309, 189-204
37. Morales, R., Estrada, L.D., Diaz-Espinoza, R., Morales-Scheihing, D., Jara, M.C., Castilla, J. and Soto, C. (2010) Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J. Neurosci. 30, 4528-4535
38. Lee, S., Fernandez, E.J. and Good, T.A. (2007) Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Aβ fibril formation pathway. Protein Sci. 16, 723-732
39. Hortschansky, P., Schroeckh, V., Christopeit, T., Zandomeneghi, G. and Fändrich, M. (2005) The aggregation kinetics of Alzheimer's β-amyloid peptide is controlled by stochastic nucleation. Protein Sci. 14, 1753-1759
40. Skerra, A. (1994) Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene151, 131-135
41. Essen, L.-O. and Skerra, A. (1994) The de novo design of an antibody combining site. Crystallographic analysis of the VL domain confirms the structural model. J. Mol. Biol. 238, 226-244
42. Yanisch-Perron, C., Vieira, J. and Messing, J. (1985) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33, 103-119
43. Moretto, N., Bolchi, A., Rivetti, C., Imbimbo, B.P., Villetti, G., Pietrini, V., Polonelli, L., Del Signore, S., Smith, K.M., Ferrante, R.J. and Ottonello, S. (2007) Conformation-sensitive antibodies against Alzheimer amyloid-β by immunization with a thioredoxin-constrained B-cell epitope peptide. J. Biol. Chem. 282, 11436-11445
44. Fling, S.P. and Gregerson, D.S. (1986) Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. Anal. Biochem. 155, 83-88
45. Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R.D. and Bairoch, A. (2003) ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 31, 3784-3788
46. Breustedt, D.A., Schönfeld, D.L. and Skerra, A. (2006) Comparative ligand-binding analysis of ten human lipocalins. Biochim. Biophys. Acta 1764, 161-173
47. Skerra, A., Gebauer, M., Hinz, D., Rauth, S. and Matschiner, G. (2011) Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target. WO 2011/069992 A2
48. Bullock, W.O., Fernandez, J.M. and Short, J.M. (1987) XL1-Blue: a high efficiency plasmid transforming recA Escherichia coli strain with β-galactosidase selection. BioTechniques 5, 376-379
49. Schmidt, T.G. and Skerra, A. (2007) The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat. Protoc. 2, 1528-1535
50. Jensen, K.F. (1993) The Escherichia coli K-12 "wild types" W3110 and MG1655 have an rph frameshift mutation that leads to pyrimidine starvation due to low pyrE expression levels. J. Bacteriol. 175, 3401-3407
51. Studier, F.W. and Moffatt, B.A. (1986) Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189, 113-130
52. Schlehuber, S. and Skerra, A. (2002) Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant - a so-called 'anticalin' - using a molecular random approach. Biophys. Chem. 96, 213-228
53. Myszka, D.G. (1999) Improving biosensor analysis. J. Mol. Recognit. 12, 279-284
54. Karlsson, R., Michaelsson, A. and Mattsson, L. (1991) Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods 145, 229-240
55. Frank, R. (2002) The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports - principles and applications. J. Immunol. Methods 267, 13-26
56. Zander, H., Reineke, U., Schneider-Mergener, J. and Skerra, A. (2007) Epitope mapping of the neuronal growth inhibitor Nogo-A for the Nogo receptor and the cognate monoclonal antibody IN-1 by means of the SPOT technique. J. Mol. Recognit. 20, 185-196
57. Sabaté, R., Gallardo, M. and Estelrich, J. (2003) An autocatalytic reaction as a model for the kinetics of the aggregation of β-amyloid. Biopolymers 71, 190-195
58. Finder, V.H. and Glockshuber, R. (2007) Amyloid-β aggregation. Neurodegener. Dis. 4, 13-27
59. Schlehuber, S., Beste, G. and Skerra, A. (2000) A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J. Mol. Biol. 297, 1105-1120
60. LeVine, 3rd, H. (1999) Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309, 274-284
61. Jarrett, J.T. and Lansbury, Jr, P.T. (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058
62. Manzoni, C., Colombo, L., Messa, M., Cagnotto, A., Cantu, L., Del Favero, E. and Salmona, M. (2009) Overcoming synthetic Aβ peptide aging: a new approach to an age-old problem. Amyloid 16, 71-80
63. Jan, A., Hartley, D.M. and Lashuel, H.A. (2010) Preparation and characterization of toxic Aβ aggregates for structural and functional studies in Alzheimer's disease research. Nat. Protoc. 5, 1186-1209
64. Ramakrishnan, M., Kandimalla, K.K., Wengenack, T.M., Howell, K.G. and Poduslo, J.F. (2009) Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid β peptide-capturing and plaque-binding monoclonal antibodies. Biochemistry 48, 10405-10415
65. Moreira, P., Pereira, C., Santos, M.S. and Oliveira, C. (2000) Effect of zinc ions on the cytotoxicity induced by the amyloid β-peptide. Antioxid. Redox Signal. 2, 317-325
66. Varadarajan, S., Yatin, S., Aksenova, M. and Butterfield, D.A. (2000) Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 184-208
67. Sun, X., Chen, W.D. and Wang, Y.D. (2015) β-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease. Front. Pharmacol. 6, 221
68. Pivtoraiko, V.N., Abrahamson, E.E., Leurgans, S.E., DeKosky, S.T., Mufson, E.J. and Ikonomovic, M.D. (2015) Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease. Neurobiol. Aging 36, 12-19
69. Haupt, C. and Fändrich, M. (2014) Biotechnologically engineered protein binders for applications in amyloid diseases. Trends Biotechnol. 32, 513-520
70. Luheshi, L.M., Hoyer, W., de Barros, T.P., van Dijk Härd, I., Brorsson, A.C., Macao, B., Persson, C., Crowther, D.C., Lomas, D.A. and Ståhl, S. (2010) Sequestration of the Aβ peptide prevents toxicity and promotes degradation in vivo. PLoS Biol. 8, e1000334
71. Wacker, J., Rönicke, R., Westermann, M., Wulff, M., Reymann, K.G., Dobson, C.M., Horn, U., Crowther, D.C., Luheshi, L.M. and Fändrich, M. (2014) Oligomer-targeting with a conformational antibody fragment promotes toxicity in Aβ-expressing flies. Acta Neuropathol. Commun. 2, 43
72. Tjernberg, L.O., Naslund, J., Lindqvist, F., Johansson, J., Karlstrom, A.R., Thyberg, J., Terenius, L. and Nordstedt, C. (1996) Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271, 8545-8548
73. Abelein, A., Abrahams, J.P., Danielsson, J., Gräslund, A., Jarvet, J., Luo, J., Tiiman, A. and Wärmländer, S.K. (2014) The hairpin conformation of the amyloid β peptideisan important structural motif along the aggregation pathway. J. Biol. Inorg. Chem. 19, 623-634
74. Lichtenthaler, S.F. (2011) α-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. J. Neurochem. 116, 10-21
75. Bateman, R.J., Aisen, P.S., De Strooper, B., Fox, N.C., Lemere, C.A., Ringman, J.M., Salloway, S., Sperling, R.A., Windisch, M. and Xiong, C. (2011) Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1
76. Nilsberth, C., Westlind-Danielsson, A., Eckman, C.B., Condron, M.M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D.B. and Younkin, S.G. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat. Neurosci. 4, 887-893
77. Levy, E., Carman, M.D., Fernandez-Madrid, I.J., Power, M.D., Lieberburg, I., van Duinen, S.G., Bots, G.T., Luyendijk, W. and Frangione, B. (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124-1126
78. Tagliavini, F., Rossi, G., Padovani, A., Magoni, M., Andora, G., Sgarzi, M., Bizzi, A., Savoiardo, M., Carella, F. and Morbin, M. (1999) A new βPP mutation related to hereditary cerebral haemorrhage. Alzheimer's Rep. 2, S28
79. Grabowski, T.J., Cho, H.S., Vonsattel, J.P., Rebeck, G.W. and Greenberg, S.M. (2001) Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 49, 697-705
80. Tycko, R., Sciarretta, K.L., Orgel, J.P. and Meredith, S.C. (2009) Evidence for novel β-sheet structures in Iowa mutant β-amyloid fibrils. Biochemistry 48, 6072-6084
81. Hendriks, L., van Duijn, C.M., Cras, P., Cruts, M., Van Hul, W., van Harskamp, F., Warren, A., McInnis, M.G., Antonarakis, S.E., Martin, J.J. et al. (1992) Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat. Genet. 1, 218-221
82. Lührs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D. and Riek, R. (2005) 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Proc. Natl. Acad. Sci. U.S.A. 102, 17342-17347
83. Makin, O.S., Atkins, E., Sikorski, P., Johansson, J. and Serpell, L.C. (2005) Molecular basis for amyloid fibril formation and stability. Proc. Natl. Acad. Sci. U.S.A. 102, 315-320
84. Austen, B.M., Paleologou, K.E., Ali, S.A., Qureshi, M.M., Allsop, D. and El-Agnaf, O.M. (2008) Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's β-amyloid peptide. Biochemistry 47, 1984-1992
85. Soto, C., Sigurdsson, E.M., Morelli, L., Kumar, R.A., Castano, E.M. and Frangione, B. (1998) β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 4, 822-826
86. Legleiter, J., Czilli, D.L., Gitter, B., DeMattos, R.B., Holtzman, D.M. and Kowalewski, T. (2004) Effect of different anti-Aβ antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J. Mol. Biol. 335, 997-1006
87. Lichtlen, P. and Mohajeri, M.H. (2008) Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. 104, 859-874
88. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L.S., Porsteinsson, A.P. and Ferris, S. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322-333
89. Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X. and Aisen, P.S. (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311-321
90. Siemers, E.R., Friedrich, S., Dean, R.A., Gonzales, C.R., Farlow, M.R., Paul, S.M. and Demattos, R.B. (2010) Safety and changes in plasma and cerebrospinal fluid amyloid β after a single administration of an amyloid β monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol. 33, 67-73
91. Karran, E. and Hardy, J. (2014) Antiamyloid therapy for Alzheimer's disease - are we on the right road? N. Engl. J. Med. 370, 377-378
92. Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., Szoeke, C., Macaulay, S.L., Martins, R. and Maruff, P. (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357-367
93. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X. and Blazey, T.M. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804
94. Panza, F., Solfrizzi, V., Imbimbo, B.P., Tortelli, R., Santamato, A. and Logroscino, G. (2014) Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev. Clin. Immunol. 10, 405-419
95. Crespi, G.A., Hermans, S.J., Parker, M.W. and Miles, L.A. (2015) Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies. Sci. Rep. 5, 9649
96. DeMattos, R.B., Bales, K.R., Cummins, D.J., Paul, S.M. and Holtzman, D.M. (2002) Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267
97. Farlow, M., Arnold, S.E., van Dyck, C.H., Aisen, P.S., Snider, B.J., Porsteinsson, A.P., Friedrich, S., Dean, R.A., Gonzales, C. and Sethuraman, G. (2012) Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 8, 261-271
98. Sperling, R.A. Jack, Jr. C.R. Black, S.E. Frosch, M.P. Greenberg, S.M. Hyman, B.T Scheltens, P. Carrillo, M.C. Thies, W Bednar, M.M2011Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable WorkgroupAlzheimers Dement7367-385
99. Boado, R.J., Lu, J.Z., Hui, E.K. and Pardridge, W.M. (2010) IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol. Bioeng. 105, 627-635
100. Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J.O., Lau, W., Tissot, A.C. et al. (2014) Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49-60